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Abstract
Substance abuse is a rare but known cause of sensorineural hearing loss (SNHL). We report a case of acute SNHL in a 28-yearold man following an overdose of methamphetamine and incidental ingestion of fentanyl. On initial encounter, he had moderateto-severe hearing loss in the right ear and severe-to-profound hearing loss in the left ear in addition to acute kidney injury, liver
failure, and lactic acidosis. The patient was treated with a two-week course of high-dose steroids and expressed a subjective
improvement in hearing. This case highlights the importance of auditory testing following a drug overdose and is one of the only
documented cases of hearing loss following methamphetamine use in recent years. There is a paucity of literature regarding the
mechanism causing acute SNHL secondary to methamphetamines. Proposed etiologies include neurotransmitter depletion or
reduced cochlear blood ﬂow as possible causes of ototoxicity.
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Introduction

Case Report

Methamphetamine is a sympathomimetic amine with psychostimulant properties. It is one of the most used illicit drugs
with an estimated 4.7 million Americans reported to have
knowingly tried it at least once.1 Methamphetamine enters
well-perfused organs rapidly, including the brain, liver and
kidney increasing release and blocking reuptake of monoamine neurotransmitters such as dopamine, norepinephrine
and serotonin. Health consequences may occur including
myocardial infarction, malignant hypertension, hemorrhagic
stroke, and psychosis.2–4 Fentanyl, a synthetic opioid, has
been increasingly laced in stimulants such as methamphetamine and others which drastically increases the risk of
overdose.5 While sensorineural hearing loss (SNHL) has
been reported as a sequela of illicit drug use, there is sparse
literature describing its occurrence with amphetamine or
fentanyl overdose. We present a patient with SNHL and
concomitant myocardial injury, acute kidney injury with
rhabdomyolysis, and liver failure following an overdose of
methamphetamine and fentanyl.

The patient was a 28-year-old male who presented to the ED
after being found unconscious by his mother in his car. A glass
pipe and unmarked canister were in the car. Subsequent
urine toxicology was positive for methamphetamines and
fentanyl and the patient endorses a history of methamphetamine and cocaine use, but denies knowledge of
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fentanyl use. The patient was arousable but lethargic in the
emergency department and immediately complained of
hearing loss including all sounds except faint beeping
from machines in the room. Communication was limited to
writing. He admitted using substances in the past including
methamphetamine and cocaine, but he denied memory of
the overdosing event and details of the incident. He denied
otalgia, otorrhea, tinnitus, vertigo, and any past otologic
surgeries or hearing problems. On exam, bedside Weber
and Rinne tests on bilateral ears with a 512-Hertz tuning
fork were inconclusive as the patient expressed only
feeling the vibration and could not hear the tone. Lab
results revealed myocardial injury (troponin 5.67 ng/mL
and ST depressions on EKG), acute kidney injury with
rhabdomyolysis (creatinine 5.33 mg/dL, creatinine
phosphokinase 14,683 U/L), liver failure (INR 2.2, total
bilirubin 1.4 mg/dL, ALT/AST 8,046/9,145 IU/L), and
lactic acidosis (1.8 mmol/L). He began treatment for
SNHL with Prednisone PO 60 mg for 14 days with a 6-day
taper. Although hyperbaric oxygen treatment was recommended, the patient’s insurance did not cover the
procedure, and he declined. An audiogram taken three

days following the inciting event showed the right ear with
moderate-to-severe hearing loss (56% speech discrimination) and the left ear with severe-to-profound hearing
loss (48% speech discrimination). Results at ten days after
prednisone was started showed relatively ﬂat, bilateral, SNHL
at 80 dB in the right ear and 65 dB in the left ear with unchanged
discrimination1 and a normal type A tympanogram (Figure 1).

Discussion
Many pharmacologic agents, including antibiotics, heavy
metals, and recreational drugs, have been identiﬁed as ototoxic. Although evidence exists that establishes the mechanism by which stimulants damage the ear, few data have been
presented for amphetamine-induced SNHL. Iqbal reported
seven inpatient heavy amphetamine users in Saudi Arabia who
developed bilateral hearing loss.6 Hearing loss was recovered in
every case within four to ten days following cessation of
chronic use. The author hypothesizes damage to the neurons
and depletion of neurotransmitters to be the mechanism of
ototoxicity, but evidence establishing the mechanism of
amphetamine-induced SNHL does not exist.

Figure 1. Bilateral sensorineural hearing loss and normal tympanogram.
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Mechanisms of SNHL have been proposed for cocaine,
another widely used recreational stimulant, that may
provide clues for other stimulants. Shivapuja et al. investigated the mechanism of chronic and acute, high-dose
cocaine on ear physiology in rats. Chronic cocaine use
reduced cochlear catecholamine innervation, while acute
cocaine use reduced inner ear cochlear blood ﬂow. 7 Ischemic change of the temporal lobe is one of the leading
theories for amphetamine-induced SNHL given its
identiﬁcation in several other recreational drug overdoses
including cocaine. 8
Although our patient’s hearing loss occurred immediately following a drug overdose, our ability to pinpoint
the exact cause is limited due to polysubstance abuse and
the complex nature of the patient’s presentation. There is
no knowledge of the frequency and amount of drug use by
the patient, how much methamphetamine or fentanyl was
ingested, the timing of the intoxication or whether other
substances were consumed that are not included in the
urine toxicology panel. Future research to understand the
pathophysiology of amphetamine ototoxicity would be
beneﬁcial to guide evaluation and treatment.
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